RecruitingPhase 1NCT06371417
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Studying Antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chugai Pharmaceutical
- Principal Investigator
- Sponsor Chugai Pharmaceutical Co.Ltdclinical-trials@chugai-pharm.co.jp
- Intervention
- RAY121(drug)
- Enrollment
- 144 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- University of California-Irvine, Orange, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Northwell Health, LLC PRIME, Lake Success, New York, United States
- Hospital for Special Surgery, New York, New York, United States
- Ohio State University, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Amarillo Center for Clinical Research, Amarillo, Texas, United States
- Nerve and Muscle Center of Texas, Houston, Texas, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Westmead Hospital, Sydney, New South Wales, Australia
- Campbelltown Public Hospital, Sydney, New South Wales, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
- Box Hill Hospital, Melbourne, Victoria, Australia
- AKH - Medizinische Universitaet Wien, Abteilung fuer Klinische Pharmakologie, Vienna, Austria
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06371417 on ClinicalTrials.govOther trials for Antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07372170Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS PatientsInfanta Leonor University Hospital
- RECRUITINGNANCT07163338Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)CHU de Reims
- RECRUITINGNANCT06373926Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid SyndromeCentre Hospitalier Universitaire, Amiens
- ENROLLING BY INVITATIONPHASE1NCT06723106Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Chugai Pharmaceutical
- RECRUITINGNCT06373003Negative Antiphospholipid Syndrome: a Multicentric StudyItalian Society for Rheumatology
- RECRUITINGPHASE2NCT06747312Effect of Belimumab on Antibody Titers in Primary APS PatientsRuijin Hospital
- RECRUITINGPHASE4NCT05995600Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKESeoul National University Hospital
- RECRUITINGPHASE2NCT05983952Anti-CD38 Antibody Treating APS With ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China